Paclitaxel is one of the chemotherapy drugs used in the standard treatment of ovarian, fallopian tube, or primary peritoneal cancer that has returned or has persisted despite prior treatment. However, it is not always curative, so researchers are seeking new therapies for women with these cancers.
Cabozantinib is an investigational drug that blocks the formation of new blood vessels that tumors need to grow and spread, by targeting several proteins that help keep cancer cells alive. It has been shown in other clinical trials to be active against certain cancers (including ovarian cancer). It is a capsule that is taken orally (by mouth).
In this Gynecologic Oncology Group study, researchers are comparing daily cabozantinib to weekly paclitaxel to treat women with ovarian, fallopian tube, or primary peritoneal cancer that has returned or has persisted despite prior treatment. Women will be randomly assigned to receive either paclitaxel (given by vein) or cabozantinib.